BC Platforms today announced that it has appointed Mark Daly as the Chairman of its Scientific Advisory Board (SAB) and expanded its senior management team who will be located at its new US headquarters in Cambridge, Massachusetts, USA.
Mark Daly is a leading authority in the field of genetics and is an institute member of the Broad Institute, co-director of the Program in Medical and Population Genetics and founding chief of the Analytic and Translational Genetics Unit at Massachusetts General Hospital where he is focused on the use of genomic information in the clinical setting.
Recent appointments to BC Platforms’ senior management team include Nino da Silva, EVP and Sales and Marketing Manager Worldwide and Douglas Last, Director of Sales. Nino has extensive experience in medical informatics and technology both in research and the clinic. Most recently he was the Chief Sales Officer of Telavox AB, a fast growing software development company and previously he was Chief Executive Officer of Ecare and Executive Vice President of Mawell Ltd. Douglas has a long history in life sciences, having spent 5 years in the lab at Harvard, 15 years at Qiagen, where he started the Advanced Technology Group, and 6 years at Quanta BioSciences and Life Technologies (now ThermoFisher) where he focused on genomics analysis using PCR and next generation sequencing both as a manager and a technical specialist.
Tero Silvola, CEO of BC Platforms, commented: “We are very pleased that Mark, a leading authority in the field of genetics for the last twenty years, has chosen to join our scientific advisory team. We believe that we will benefit greatly from the advice, creativity and network that he can bring to the company. We are also pleased to have added two critical appointments to our senior management team who will be based at our new offices in Boston, by Kendall Square, a hot spot for science and innovation. Investing in these key additional resources will enable us to grow our US customer base and support our global growth over the next two years.”
Mark Daly, the new Chairman of the SAB at BC Platforms, commented on his appointment: ‘I am delighted to be joining BC Platforms at this exciting time of their growth and delighted that they have chosen to locate their US headquarters in Boston. I have been impressed by the company’s pioneering technology and the partnerships that they are forming to focus on the use of genomic information in the clinical and biobank settings which has the potential to revolutionize drug discovery and development.’
